Recurrence

·MeSH: Recurrence

23 drugs in development·21 companies·1 clinical trial

Drug Pipeline by Phase

Approved(16)

Drug	Company
enzalutamide	X4 Pharmaceuticals, Inc (XFOR)
enzalutamide	Aptinyx Inc. (APTX)
esomeprazole magnesium	EXELIXIS, INC. (EXEL)
famotidine	Mersana Therapeutics, Inc. (MRSN)
famotidine	Avita Medical Inc. (RCEL)
famotidine	Seagen Inc. (SGEN)
famotidine	Miromatrix Medical Inc. (MIRO)
famotidine	SUNSET ISLAND GROUP (SUN)
ibrance	PFIZER INC (PFE)
kisqali femara co-pack	Novartis AG (NVS)
propafenone	Mylan II B.V. (MYL)
pylarify	PROGENICS PHARMACEUTICALS INC (PGNX)
PYLARIFY	Lantheus Holdings, Inc. (LNTH)
Verzenio®	ELI LILLY & Co (LLY)
VOWST	Seres Therapeutics, Inc. (MCRB)
Xifaxan	Bausch Health Companies Inc. (BHC)

Phase 3(2)

Drug	Company
d961h	ASTRAZENECA PLC (AZN)
ibezapolstat (formerly ACX-362E)	Acurx Pharmaceuticals, Inc. (ACXP)

Phase 2(2)

Drug	Company
axa1665	Axcella Health Inc. (AXLA)
ibezapolstat	Acurx Pharmaceuticals, Inc. (ACXP)

Preclinical(1)

Drug	Company
risk of recurrence	Biodesix Inc. (BDSX)

Unknown(2)

Drug	Company
Precise MRD	MYRIAD GENETICS INC (MYGN)
Precise MRD (minimum residual disease)	MYRIAD GENETICS INC (MYGN)

BioSniper tracks 23 drugs in development for Recurrence across 21 companies.

There are 1 clinical trial targeting Recurrence tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.